5 From prevention to personalized risk stratification Success in primary prevention may shift how we assess risk: biomarker stratification, genetic risk scores, imaging of subclinical disease may become more important in selecting who should get aggressive lipid-lowering early
After 12 months of treatment, people who took: Tirzepatide lost an average of 15% of their body weight Semaglutide lost an average of 8% of their body weight While the potential weight loss outcomes with both drugs are promising, these medications arent a cure-all
PlexusDx maps 14 peptide pathways and 150+ genetic insights to help your healthcare provider adjust your starting dose, escalation schedule, or even recommend a complementary compound like tirzepatide for better tolerance
Patients frequently ask me if this "gut healing peptide" can treat inflammation, reverse a leaky gut, or manage irritable bowel syndrome (IBS) flares
Although functional heterogeneity within the GSH-low hES-MSC population remains unclear, it is more likely that GSH-low hES-MSCs are more heterogeneous and may consist of a mixture of cells in various states, including senescent and unhealthy states